2025年四季度新兴技术指标（英）

Investment Rating - The report indicates a strong investment rating for the Emerging Tech sector, particularly in AI and healthcare, with record capital deployment in 2025 [6][16]. Core Insights - Top investors are significantly increasing their investments, with ETI funding reaching $33.1 billion across 874 deals in 2025, marking a record despite lower deal counts compared to previous years [6][16]. - AI investments are at an all-time high, with 51.6% of ETI deals in Q4 2025 directed towards AI startups, surpassing the broader venture space [6][50]. - The trend towards larger deal sizes is evident, with rounds exceeding $50 million and $100 million becoming more common, reflecting a shift in investor strategy towards fewer, higher-value bets [6][17]. Deal Activity - In Q4 2025, top investors participated in 225 seed and early-stage deals totaling $10.5 billion, matching previous quarterly peaks despite lower transaction volumes [16]. - The concentration of funding in megadeals is notable, with three companies raising $2 billion each, capturing 18% of all ETI capital [17]. - The median deal sizes for ETI startups are significantly higher than the broader VC market, with pre-seed/seed median deal sizes at 3.3 times the overall VC median [18][19]. Areas of Investment - AI/ML remains the dominant segment, capturing $5.3 billion across 53 deals in Q4 2025, with significant activity in vertical applications such as fintech and healthtech [23][49]. - Healthtech & wellness saw a substantial increase in activity, reaching $678 million across 23 deals, driven by consumer healthcare technologies and AI-enabled solutions [66]. - Cybersecurity investments surged to $643.1 million in Q4 2025, with a focus on AI-native platforms due to the rise of AI-powered threats [79]. Notable Activity - The fintech sector recorded $682.8 million across 24 deals in Q4 2025, with significant investments in AI-native platforms [107]. - The largest non-AI ETI round was Tempo's $500 million Series A for a blockchain platform, highlighting continued interest in innovative financial technologies [108]. - Biotechnology is showing signs of recovery, with 10 deals in Q4 2025, reflecting renewed investor interest in high-value, clinical-stage assets [87].